Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821

C 1821 is a purified glycoprotein extract of Klebsiella pneumoniae serotype 2 with immunomodulating properties in animals (in vivo and in vitro) and in humans (in vitro). The compound is devoid of any apparent toxicity when given orally. The aim of the present work was to evaluate the effects of a s...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology Immunotherapy 1982-01, Vol.14 (1), p.59-60
Main Authors: Lang, J M, Giron, C, Aleksijevic, A, Marchiani, C, Zalisz, R, Oberling, F
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Aged
Female
Glycoproteins - administration & dosage
Hodgkin Disease - drug therapy
Hodgkin Disease - immunology
Humans
Hypersensitivity, Delayed - immunology
Klebsiella pneumoniae
Lymphoma - drug therapy
Lymphoma - immunology
Male
Middle Aged
Neoplasms - drug therapy
Neoplasms - immunology
Short Communication
Skin Tests
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:C 1821 is a purified glycoprotein extract of Klebsiella pneumoniae serotype 2 with immunomodulating properties in animals (in vivo and in vitro) and in humans (in vitro). The compound is devoid of any apparent toxicity when given orally. The aim of the present work was to evaluate the effects of a short term oral administration of C 1821 on delayed cutaneous hypersensitivity to recall antigens in untreated cancer patients (mostly lymphomas). Consecutive patients were alternately allocated to receive C 1821 or placebo for 14 days. C 1821 restored and significantly (P less than 0.02) enhanced skin reactions, as shown using the Multitest system.
ISSN:0340-7004
1432-0851
DOI:10.1007/BF00199434